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Abstract: 
Introduction: Macromolecules with unique effects and potency are increasingly being 
considered for application in lung pathologies. Numerous delivery strategies for these 
macromolecules through the lung, have been investigated to improve the targeting and 
overall efficacy. 
Areas covered: Targeting approaches from delivery devices, formulation strategies and 
specific targets are discussed.  
Expert opinion: Although macromolecules are a heterogeneous group of molecules, a 
number of strategies have been investigated at the macro, micro and nanoscopic scale for the 
delivery of macromolecules to specific sites and cells of lung tissues. Targeted approaches 
are already in use at the macroscopic scale through inhalation devices and formulations, but 
targeting strategies at the micro and nanoscopic scale are still in the laboratory stage. The 
combination of controlling lung deposition and targeting after deposition, through a 
combination of targeting strategies could be the future direction for the treatment of lung 
pathologies through the pulmonary route. 
 
Keywords: Aerosol Devices, Inhaled Macromolecules, Lung Delivery, Microcarrier, 
Nanocarrier, Nanomedicine, Lipid-based systems, Passive and Active Targeting, Pulmonary 
Pathologies   
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LIST OF ABBREVIATIONS 
• Macromolecules for treatment of lung pathologies are heterogenous and can range 
from proteins such as antiproteases in cystic fibrosis to genetic material such as 
siRNA in asthma. 
• Aerosolization is the main form of delivering materials to the lungs. 
• Particle based carriers have been investigated for delivery of macromolecules, as 
they can be made with specific physicochemical properties to suit a variety of 
macromolecules and also allows for controlled release and targeting. 
• Targeting can be in the form of passive or active targeting, referring to utilizing the 
unique physiological characteristics of the target environment, or specifically 
targeting molecules or components of the cell surface, respectively. 
• Only a few molecular targets have been investigated for active targeting through the 
pulmonary route but a considerable number have been identified and could be 
possible avenues for future investigation. 
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ACE  Aerosol Cloud Enhancer 
APC Antigen-Presenting Cells 
ARCs Archaeosomes 
ARDS Acute Respiratory Distress Syndrome 
BCG Mycobacterium Bovis Bacille Calmette-Guérin 
BSA Bovine Serum Albumin 
CF Cystic Fibrosis  
CFTR Cystic Fibrosis Transmembrane Conductance Regulator  
COPD Chronic Obstructive Pulmonary Disease 
CPV Canine Parvovirus 
DCs Dendritic cells 
DNA Deoxyribonucleic acid 
DPIs Dry Powder Inhalers 
dsRNA Double-Stranded Ribonucleic Acid 
EGFR Epidermal Growth Factor Receptor 
FPF Fine Particle Fractrion 
HA Hyaluronic acid 
hpIgR Human Polymeric Immunoglobulin Receptor 
IPF Idiopathic Pulmonary Fibrosis  
LHRH Luteinizing Hormone Releasing Hormone 
lncRNA Long Non-Coding Ribonucleic Acid  
MDIs Metered Dose Inhalers 
miRNA Micro Ribonucleic Acid 
MMP9 Matrix Metallopeptidase 9 
MPs Microparticles 
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MW Molecular weight 
NCMPs Nano-composite Micro Particles 
NPs Nanoparticles 
O-SAP O-Steroyl Amylopectin 
PAMAM Polyamidoamine 
PCD Primary Ciliary Dyskinesia 
pDNA Plasmid Deoxyribonucleic acid 
PEG Polyethylene Glycol 
PEI Polyethylenimine 
PGA-co-PDL Poly (Glyceroladipate-Co-ᵚ-Pentadecalactone) 
PLGA Poly Lactic-Co-Glycolic Acid 
PLL Poly (L-Lysine) 
PspA Pneumococcal Surface Protein A  
RNA Ribonucleic Acid 
SFNPs Silk Fibroin Nanoparticles  
siRNA Small interfering Ribonucleic Acid  
SLPI Secretory Leukoprotease Inhibitor  
SLS Solid lipid nano- and micro-structures 
ssRNA Single-Stranded Ribonucleic Acid 
TB Tuberculosis 
Tf-PEI Transferrin-Polyethylenimine  
tgAAVCF Adeno-Associated Virus Vector Encoding The Human       
TPL Triptolide 
VEGF Vascular Endothelial Growth Factor  
1. Introduction  
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Pulmonary pathologies are main causes of morbidity and mortality worldwide, such as 
respiratory infections, chronic obstructive pulmonary disease (COPD), lung cancer, and 
asthma. Lung delivery of macromolecules through different carrier systems has gained 
increasing attention for the treatment of respiratory diseases and this review aims to provide a 
concise, up-to-date overview of recent advances in delivery strategies of macromolecules via 
inhalation to treat pulmonary pathologies.  
1.1. Pulmonary Route for Inhaled Macromolecule Drug Delivery: 
The pulmonary route is composed of two structural parts that have different physiological 
characteristics (Figure 1); the conducing airways and the respiratory airways. The conducting, 
or, upper airways, extend from the nose, pharynx, trachea and to the terminal bronchioles, 
branching approximately 17 times until reaching the respiratory bronchioles. The conducting 
part has pseudo-stratified columnar ciliated epithelium with mucous secreting cells, which are 
responsible for the mucociliary clearance of the airstream from any exogenous particles, dust, 
and bacteria. The thickness of the epithelium is approximately 60 µm with a thick mucus layer 
lined with a lung surfactant layer [1]. The surface area is about 2 m2. The main functions are to 
transport the air to the gas-exchange area and to humidify, adjust the temperature, and filter of 
the incoming air stream.  
There are numerous factors that can contribute to the sub-optimal delivery of aerosolized 
carriers or macromolecules in the conducting airways. One factor is the deposition of 
aerosolized matter against the walls of the airway. The size, shape and density of particles can 
influence the deviation of particle flow from the streamlines and result in subsequent 
impaction away from the main absorptive alveolar surface. Another factor is the humid internal 
environment (approaches 90%), which can increase of the size of the hygroscopic particles and 
favors their deposition and early mucociliary clearance [2]. Underneath, the tight junctions 
between the epithelial cells presents as another barrier for carrier and macromolecule flux. The 
Ac
ce
pte
d M
an
us
cri
pt
7 
 
conducting airway is associated with common diseases such as asthma, COPD, CF, and 
emphysema. The pathophysiology is variable according to the disease conditions leading to 
bronchoconstriction and increase in the pulmonary tension with resistance to the air flow. 
 
The respiratory airways are distal to the terminal bronchioles (branching around 8 times) 
ending in alveolar sacs. There is a very thin (0.2-2 µm thickness) epithelium of alveolar cell 
type I (main cells) and type II secreting lung surfactant layer. The wide surface area (100-140 
m2) is responsible for gas exchange and shows the highest permeability to water and 
macromolecules making it suitable target for drug delivery. Tight and gap junctions are the 
main connections between the alveolar cells [3]. A blood-air barrier formed from a single 
fused basal lamina of alveolar cells and endothelium, hosting a plethora of cells like dendritic 
cells (DCs), mast cells and lymphocytes with secretory immunoglobulin. They not only play a 
role in antigen recognition and allergic reactions [4, 5], but wandering alveolar macrophages 
that engulf foreign substances can be another barrier for carrier and macromolecule delivery. 
The absorption of deposited particles in the alveolar barrier is through either receptor-mediated 
transcytosis, paracellular passive transport via tight junctions, endocytosis, and engulfed by 
macrophages [6]. Size and molecular weight (MW) are important factors controlling the 
macrophage uptake; MW ≤ 25 kDa are rapidly cleared while MW ≥ 40 kDa are slowly cleared, 
whereas, phagocytosis is optimal for particle size of 1.5-3 µm. To escape the macrophage 
clearance mechanisms, drug particle and delivery systems must outside of the size range 
recognized by the macrophages [7]. For macromolecules, e.g., peptides, proteins, 
siRNA/miRNA, the lung surfactant may induce aggregation, and thus, potentially enhance 
macrophage clearance. Furthermore, the macrophages secrete peroxidases, 
inflammatory/immunomodulatory mediators and other host defense molecules that can 
degrade macromolecules and initiate a local immune response [8, 9]. Disease conditions 
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affecting the alveoli have serious percussions to the gas exchange, such as tuberculosis (TB), 
lung cancer, emphysema, pneumonia, acute respiratory distress syndrome (ARDS), and 
pulmonary edema. The pathophysiology of the respiratory tract and the severity of the disease 
are other limiting factors for successful macromolecule delivery.  
1.2. Macromolecules and Challenges For Pulmonary Delivery:  
The successful production and marketing of the first human recombinant insulin occurred over 
three decades ago as a protein drug, and subsequent development and production of 
macromolecule use for theranostic applications has been a rapidly evolving area of 
pharmaceutical industry [10]. Macromolecules are a heterogeneous group of proteins, 
including small peptides (20–30 amino acid residues, or called oligopeptides) (cytokines, 
enzymes, vaccines, monoclonal antibodies and clotting factors), and genetic material (DNA, 
pDNA, RNA, siRNA, miRNA, ribozymes and aptamers). They are molecules with superior 
drug-like properties such as potency and specificity, due to highly selective receptor-binding 
which minimize off-target side effects. However, due to their large size, hydrophilicity, MW, 
structural instability, and subsequent limited absorption at port of entry, their delivery has 
predominantly been conducted through injection. Short-circulatory half-life presents with 
another limitation, requiring frequent injections and consequently lowering the patient 
adherence to the treatment [11]. Aerosolized macromolecule delivery therefore has promising 
potentials as an alternative method for their delivery. Such potential benefits include non-
invasiveness, possibility for self-administration, bypassing hepatic metabolism and avoidance 
the harsh proteolytic oral environment. Furthermore, the large surface area (100-140 m2 in 
humans) of the lungs with abundantly vascularized thin epithelium, offers an encouraging 
route for local topical and systemic delivery. Increased bioavailability of the bioactive with a 
rapid onset of action, requiring smaller doses and reducing the potential unwanted side effects, 
are among advantages of macromolecule delivery via aerosol inhalation [12].  
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However, inhalation of macromolecules includes many challenges in their formulation, 
storage, and delivery [13]. Manufacturing and purification of macromolecules is a very costly 
process. Traditional methods of highly purified animal tissue protein extracts are hampered 
with immunogenicity and lack of specificity [14]. The newer recombinant macromolecule 
production lines are improving to increase the quantity and the quality of the macromolecules 
and reducing the cost, which is still very high. Using transfected mammalian cell lines, and 
recently, human cell lines, are more advantageous than E. coli clones with better similarity of 
macromolecules structure to the natural human proteins, albeit with high cost [14]. 
Macromolecules have unique structural features and their activity is closely related to their 
structural integrity, which makes their formulation challenging. Different aerosol formulation 
approaches (e.g. dry powder, aqueous solution, liquid solution/suspension in a propellant 
vehicle), are incorporated to preserve their structural integrity. Most carrier based formulations 
aim to encapsulate the macromolecules in their core to evade exposure to any enzymatic 
degradation. The carriers/formulations are equipped with different shielding in order to evade 
macrophages uptake, and targeting moieties can localize the active agent in the required site. 
Various stabilizers, absorption enhancers, and mucoadhesive adjuvants, such as fatty acids, 
surfactants and protease inhibitors, have been utilized to promote higher bioavailability [9, 15, 
16]. Furthermore, the optimal choice of aerosol delivery device is influenced by the 
macromolecule type, lung target site and condition.  
The safety profiles, including toxicity, local and systemic side effects, and immunogenicity, 
are important criteria in macromolecules evaluation, in addition to the efficacy and shelf life. 
In fact, many macromolecules have a major risk of inducing immunogenic reactions [17], with 
antibody production as the primary immune response. The therapeutic agent, after recognition 
as ‘foreign’, is internalized, processed, and presented by antigen-presenting cells (APC), 
resulting in CD4 T-cell responses and the elevation in antibody titer. This immunogenic 
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reaction can be used to our advantage and is sometimes targeted as in vaccine prophylaxis and 
therapeutics [5].  
The literature reports that many small RNA, such as siRNA, miRNA and ribozymes could be 
potential powerful therapeutics [18, 19]. On the other hand, a wide variety of RNA species or 
analogues have also been reported to be immunogenic including ssRNA and dsRNA [20]. The 
investigation of the immune-compatibly represents one of the most important features for their 
translation to the clinic. A wide range of physicochemical properties such as MW, size, surface 
charge, solubility, and hydrophobicity play a role in macromolecule safety [17]. Hence, the 
interplay of macromolecule properties, formulation/carrier characteristics, device type, and the 
targeted lung disease are to be predetermined to achieve successful delivery (Figure 2). 
2. Aerosolized Delivery Strategies for Macromolecule Drug Delivery:  
Drug delivery to the lungs is achieved via respirable aerosols and can be used for topical as 
well as systemic delivery because of the advantages offered by the pulmonary route over other 
systemic routes of administration [9]. The aerosol is a stabilized dispersion of solid or liquid 
droplets suspended in a gaseous vehicle. The size of these droplets is always referred to as an 
aerodynamic diameter; the diameter of a sphere of a unit density with the same settling 
velocity as the particle of interest. The inhalable portion of an aerosol is with an aerodynamic 
diameter below 10 µm and classified into coarse particles > 2 µm, fine particle fraction (FPF) 
0.1-2 µm, ultrafine fraction < 0.1 µm [9]. Most of pharmaceutical aerosols are polydisperse but 
newer formulations and devices are developing monodisperse systems. It is generally accepted 
a size range for pharmaceutical applications between 0.5-5 µm will allow deposition in the 
respirable airways [1]. The aerosol deposits the drug into the airways via different mechanisms 
mainly inertial impaction, gravitational settling, interception, and Brownian diffusion. The 
pharmaceutical aerosols which have a positive charge will be exposed to electrostatic 
precipitation (Figure 3A, B) [21, 22]. A number of factors contribute to the deposition of 
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aerosol particles to the airway targets; mainly particle characteristics; size, shape, density and 
charge, and the pathophysiology of the respiratory system. These factors are not only 
determinants for the quantity of the deposited particles but also to which regions of the 
respiratory airways are depositional targets [9]. It has been noted for optimal aerosol delivery, 
the conditions are aerosol particles with an aerodynamic diameter 0.5-5 µm and lung flow rates 
of 15-30 liter/minute [21, 23].   
2.1. Aerosol Generating Devices: 
Three widely known systems for aerosol drug delivery are nebulizers, metered dose inhalers 
(MDIs), and dry powder inhalers (DPIs). The choice of the device is multifactorial 
dependent on the active agent, the formulation characteristics, the target site and the 
pulmonary pathophysiology. The main advantages and disadvantages of each device with 
recent insights for their development toward macromolecules delivery are represented in 
Table 1. Successful aerosol delivery to the lung should maintain high efficacy, dose-
reproducibility, site-specificity, enhanced aerosol FPF, durability and stability for multiuse, 
simple handling, environmental-friendly, risk-free, and cost effective treatment [1, 24-29]. 
Examples of local aerosol macromolecules delivery to the lung are summarized in Table 2.    
2.2. Carrier delivery systems: 
A carrier delivery system allows an active agent to be stably encapsulated or adsorbed, aiming 
to improve the pharmaco-kinetics and -dynamics. The carriers can be conveniently used to 
improve the stability, prevent macromolecule degradation, increase cellular uptake, and confer 
efficient targeting to the site of action with a homogenous distribution and favorable retention, 
with a reduced side effect by shielding (Figure 4A) [24]. The carriers are ideally 
biocompatible, biodegradable, and non-immunogenic, with high stability and scalability [21, 
30]. The carrier selection is dependent on interplay of factors mentioned in Figure 2. For 
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successful aerosol delivery of macromolecules, preconditioned understanding of 
macromolecule and aerosol characteristics, target pathophysiological lung condition 
(inspiratory flow, lung volumes, breath-holding) and the suitability and stability of the 
macromolecule aerosol generated by nebulization, MDIs, and DPIs is required [1].  
2.2.1. Polymeric Particulate Carriers:  
Microparticles and Nanoparticles: Although the defined size ranges for microparticles 
(MPs) and nanoparticles (NPs) can differ based on convention and sources [31], NPs will be 
referred to particles within the nanometer scale, (1-1000 nm) and MPs as particles in the 
micrometer scale (1-1000 µm) for the purpose of discussing pharmaceutical carrier 
formulations in this review, NPs and MPs have a variety of physicochemical properties such as 
size, surface area, shape, molecular weight, porosity, hydrophobicity and charge, that allow 
modifications and functionalization to suit a wide range of macromolecules (Figure 4B) [24, 
32]. These carriers offer high loading capacity, protection from enzymes resulting in improved 
macromolecule stability with enhanced lung distribution and retention. Furthermore, they can 
be actively targeted to the site of action and have mechanisms for controlled release with a net 
gain of reduced dosing frequency and improved patient compliance. Moreover, they can be 
easily formulated from a wide variety of natural and polymeric biodegradable and 
biocompatible materials such as chitosan, alginate, poly Lactic-co-Glycolic acid (PLGA), 
polyethylenimine (PEI), poly (l-lysine) (PLL) [33]. However, the formulation processes to 
produce NPs and MPs from the above polymers include harsh steps and solvents that can 
potentially denature the macromolecule or alter its structure such as emulsification/solvent 
evaporation, spray dryer, freeze dryer, supercritical fluid technology [34, 35].  
Prior optimization steps are required to improve loading and stability. For example, surface 
coating or functionalization improves the pharmacokinetics; particle shielding with lipids or 
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hydrophilic polymers as polyethylene glycol (PEG) lowers the macrophages uptake and 
recognition, mucoadhesive particles increase the lung retention, i.e., chitosan, coating of 
carriers with active targeting ligands such as antibodies will be discussed later [32]. A study 
showed a promising co-block polymer poly(glyceroladipate-co-ω-pentadecalactone), (PGA-co-
PDL) MPs with PEG as a suitable carrier for mucolytic enzyme as a protein model; α-
chymotrypsin that showed high loading and suitability for DPI [36]. It is also difficult to 
deliver NPs in their single particulate form due to their high aggregation properties that favor 
their clearance. Consequently, NPs have been incorporated within microcarrier systems via 
spraydrying using sugars and amino-acids into NPMPs [37]. Their main advantages are 
evading the mucociliary and macrophages clearance. Upon their delivery to lower airways, the 
MPs degrade releasing the NPs that contain the active agent. They show successful DPI 
formulation with both good flow-ability and dispersibility. Kunda et al., showed successful 
polymeric cationic NPs formulation loaded with a Bovine Serum Albumin (BSA) as a protein 
model and was developed into DPI with good biocompatibility against A549 cell line [38]. 
Furthermore, they successfully developed a NPMPs loaded with pneumococcal surface protein 
A (PspA) as DPI vaccine against pneumococcal infection that successfully induced antibody 
response against in-vitro DCs line [38]. Recently this work was continued by Rodrigues et al., 
which demonstrated successful vaccination antibody production through in-vivo study via lung 
instillation in mice compared to subcutaneous injection [39].  
Cationi  polymers are receiving increasing interest as non-viral vectors for gene transfer such 
as PLL, PEI, chitosan, dextran, although the transfection rates are still low compared to 
viral/plasmid vectors [21, 24, 38, 40]. However, they are less immunogenic with anti-
degradation shielding. In addition, their cationic charge may play a role in the improved 
cellular uptake as well as increase the risk of local toxicity due to the interaction with cell 
membrane, so extensive optimization is prerequisite. A double-blinded clinical trial of PEG-
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PLL NP-mediated gene delivery for CF; where a gene was transfected though nasal mucosa; 
showed promising results [41]. 
Dendrimers: Dendrimers are highly branched polymeric carriers that have terminal amine, 
carboxyl, or hydroxyl groups and their size is within nano-scale (Figure 4C). These groups 
provide a platform for functionality with different targeting and therapeutic molecules. Their 
branched structure effectively encloses active (hydrophilic or lipophilic) agents. They have 
improved physicochemical properties and based on biocompatible and biodegradable 
polymers. Uniform size with (low polydispersity), stability, versatile ability for modifications, 
amine group-transfection ability enhances their carrier properties [32, 42]. However, the 
complex formulations with multifaceted steps to access the core and build branches are 
limiting factors. Polyamidoamine (PAMAM) dendrimers of different sizes were tested in-vitro 
(Calu-3, primary alveolar cell lines), ex-vivo (instillation into perfused rat lungs) to show 
successful uptake intracellular with no aggregation with the lung fluid. They showed 
promising results for biocompatible targeting the lung via inhalation [43].  
2.2.2. Lipid based Carriers:  
Lipid based carriers are efficaciously used in aerosolized macromolecules delivery offering 
high stability of the formulation and long storage life. They provide protection against 
enzymatic breakdown and mucociliary or phagocytic clearance with reduced toxicity and 
immunogenicity. They can provide controlled or sustained release with enhanced cellular 
uptake with intracellular cargo delivery and suitable for hydrophilic/lipophilic active agents, 
and can be functionalized with targeting moieties to certain cells [24, 44].  
Liposomes: Liposomes are phospholipids assembled vesicles possessing an aqueous core with 
a size range within the nano to micrometre scale (Figure 4D). They can be formulated from 
natural or synthetic lipids mostly with neutral or anionic charge such as phosphatidylcholines, 
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sphingomyelins, phosphatidylglycerols, and phosphatidylinositols [32]. However, cationic 
liposomes are produced using lipids with a positive charge and are used for gene delivery due 
to their capability for ionic interactions with DNA, siRNA/miRNA [24, 32]. They form single 
bilayer or multilayers that can be used for the controlled release, encapsulate 
hydrophilic/lipophilic active agents and improve loading capacity, versatile chemical 
functionalization, and active targeting. Liposomes are extensively investigated carriers for a 
wide variety of drugs and macromolecules and can be locally delivered via nebulization or DPI 
[24, 45]. Lung deposition and retention can be targeted via modifications of the 
physicochemical characters such as size, charge, and formulation composition ratio and lipid 
type. Liposomes have been used as delivery carriers for vaccines [46], nucleic acids such as 
siRNA, miRNA, lncRNA, DNA for respiratory conditions as in COPD, CF, lung cancer, 
although some of these applications are commonly administered via invasive routes, a number 
of cell and animal studies have proved their suitability for local lung delivery [44, 47, 48].   
Solid lipid nano- and micro-structures (SLS): SLS are colloidal carriers having a core of 
solid lipids and a shell of biocompatible stable emulsifiers as phospholipids, bile salts, poly 
(vinyl alcohol) (Figure 4E) [49]. They offer improved stability, higher loading, scalability and 
shielding polymers are used to modify their surface reducing their phagocytic clearance.  
PulmoShperes™ are porous carriers that can be formulated from lipid-based emulsion spray 
dried coarsening with a shell of monolayers of phospholipids. They can incorporate the active 
agent in the core and delivered via inhalation device or instillation. They have been 
investigated in different clinical trials mainly for delivery of antibiotics but showing promising 
results for delivery of macromolecules as vaccine, peptides and antibodies [50, 51]. 
Archaeosomes (ARCs): ARCs are lipid based carriers formulated from a polar type of lipids 
derived from archae membrane lipid of bacteria; Sulfolobus acidocaldarius. This lipid has di- 
or tetra-ether groups and has enhanced properties as gene carriers and macromolecules. They 
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carriers are biocompatible and biodegradable with high stability cationic lipids with versatile 
functionality. ARC-DNA complexes were delivered via lung cell line A549 as model therapy 
for CF [52, 53]. 
2.2.3. Other carriers for pulmonary delivery: 
Viral DNA/iRNA vectors: Viral vectors as gene transfection agent are well renowned such as 
retroviruses, adeno- and adeno-associated viruses. However, their use and investigation as 
carriers for pulmonary delivery is limited with majority of administration via parenteral route. 
Their main limitations are immunogenicity, limited loading, and poor scalability. Human CF 
transmembrane conductance regulator (CFTR) cDNA that was successfully loaded into 
adenovirus associate (tgAAVCF) had passed clinical trial phase I via nebulizers in CF patients, 
however was discontinued after failing to achieve the therapeutic targets in phase II [54]. 
Another study investigated the delivery of miRNA (Let-7) through lentivirus vectors in mouse 
lung cancer model resulted in tumor suppression against non-small cell lung cancer [55]. 
Plasmid-DNA complex have also been investigated using bacteriophages, such as 
bacteriophage ɸC31 integrase to enhance the efficiency of delivery [54, 56]. 
Cell-based, biomimetic, and stem cells: Recent advances have enabled using cellular based 
products for drug delivery purposes, such as using blood cells membrane but at present, no 
such aerosolized drug is found nonetheless that would be inspirational for future inhaled 
therapeutics [57]. 
3 General Approaches for Targeting Pulmonary Delivery of Macromolecules 
There are a number of approaches for targeting macromolecules and delivery vehicles to 
specific locations of lung tissue. Such targeted delivery in the lungs is an important aspect of 
increasing the concentration of drug to area of interest, which will ideally result in improved 
efficacy of drugs at the target site, as well as reduced systemic side effects. These methods for 
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influencing the destination of active macromolecules can be categorized into passive and 
active forms of targeting, which refer to utilizing the unique physiological characteristics of the 
target environment, or specifically targeting molecules or components of the cell surface, 
respectively. 
Passive targeting: The most common form of passive targeting within the lungs is by utilizing 
the discriminative tendencies of the airway physiology to influence the localization and 
deposition of the formulation. This bias and inequality in lung localization can arise initially 
due to how the delivery vehicle transits along the inhalation airflow and through the airways of 
the lungs. A widely utilized approach of passive targeting in the lungs is through control of 
particle size in the aerosol, which can be in the form of either suspended liquid or solid, to 
influence the aerodynamics; dictating the principal mechanisms of impaction. Such methods 
have been utilized in inhalation therapy for nearly 200 years and can be seen utilized in 
metered dose inhalers, nebulizers and dry powder inhalers.  
It is well established that aerosol particles with aerodynamic diameters in the range of 1 to 5 
µm reach the lower parts of the respiratory tract, whereas particles smaller than 1 µm do not 
deposit, and particles larger than 5 µm accumulate in the conducting airways [58]. Knowing 
that the deeper alveolar regions of the lungs exhibit greater drug absorption, as well as immune 
response in the case of immunotherapies, the optimum size range of 1-5 µm is generally the 
aim for contemporary pulmonary formulations. The particle physicochemical characteristics 
can be adjusted and utilized to achieve targeting to the desired lung region [59]. The targeted 
deposition in the lungs is an important mechanism for formulations such as particles 
containing itraconazole or amphotericin B for lung infections, and has been shown to increase 
the efficacy of the treatments [60]. Due to the concentration dependent effect of some 
antibiotics, it is important to have targeted delivery to ensure high concentration only at the 
affected sites in order to ensure optimum effects while avoiding side effects. Although small 
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molecules such as antibiotics and airway therapeutics make up the majority of the delivered 
material, macromolecules such as siRNA have been heavily considered for pulmonary delivery 
[61].  
Nanoparticulate formulations, such as polymeric NPs or liposomes, can exhibit controlled drug 
release at the site of delivery, leading to maintenance of therapeutic concentrations in the lungs 
for a longer duration [62]. Another unique property of NPs is the tendency to be phagocytosed 
by alveolar macrophages, if they are in the range of 500 to 3000 nm [63, 64]. The simultaneous 
effects, of NPs uptake and release, were demonstrated simultaneously, when a study of 
multilamellar liposomes containing rifampicin and isoniazid, exhibited presence in alveolar 
macrophages and could maintain therapeutic concentrations in the lung tissue for 5 days [65]. 
Antimicrobial delivery via liposomes to the lungs, has been shown to be beneficial in the case 
of cystic fibrosis and exhibit a controlled and sustained release and some are currently in phase 
II clinical trials [66]. Studies involving the delivery of macromolecules such as siRNA  have 
also been conducted using nanocarriers, as summarized more in depth elsewhere [61].  
Other than aerosols, liquid micro volumes can also be administered by an airway catheter or 
bronchoscope to target specific areas of the lungs, but is generally thought to be invasive. 
Recent development of the delivery of micro-volumes of a liquid plug, by controlling liquid 
volume and air v ntilation, has been hypothesized to be a potential approach for the targeted 
delivery of precise drug dosages to specific areas in the lung to treat pathologies such as cystic 
fibrosis and lung cancer [67]. 
Passive targeting in the lung can be summarized as changing the characteristics of the delivery 
vehicle to influence localization and uptake based on the physiology of the lung and cellular 
composition. Optimizing the characteristics of the aerosolized particles comprises a large 
aspect of this targeting approach as seen in the numerous aerosol delivery devices (Table 1). 
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Active targeting: Targeting specific tissue locations, cells, molecules on cells and cell 
compartments, to increase the concentration of therapeutic macromolecules at the precisely 
desired location, is the hallmark aim of active targeting. One of the ubiquitous approaches for 
active targeting generally involves the conjugation of the carrier or macromolecule to a 
targeting ligand, which is generally in the form of protein and peptides, polysaccharides, 
glycolipids, glycoproteins or antibodies. Cell surface receptors may be overexpressed on 
specific cell groups according to the pathologies such as cancer, or expressed on a particular 
cell group that are useful targets for therapy [68]. 
For lung cancer, several targets, which can be used to discriminate between healthy and 
cancerous cells, have been discovered. The epidermal growth factor receptor (EGFR) is known 
to be highly expressed in non-small cell lung cancer, and studies have been conducted 
investigating nano-formulations with EGFR targeting ligands for the delivery of cisplatin to 
the cancer tissue following inhalation [68]. These EGFR targeting particles were able to reduce 
tumor volume more effectively, as well as increase the bioavailability of cisplatin in the lung 
compared to the free drug [68]. Another target for lung cancer is carbonic anhydrase IX, which 
is expressed on tumor cells. Carbonic anhydrase IX antibody was incorporated onto liposome 
particles with CPP33, which is a cell-penetrating peptide. These liposomes loaded with 
Triptolide were shown to exhibit anti-tumor effects and reduced systemic side effects when 
administered endotracheally. Luteinizing hormone releasing hormone (LHRH) receptors are 
also known to be overexpressed on lung cancer cells and have been successfully investigated 
for selective targeting [69]. siRNA delivery to cancer cells using nanocarriers targeting LHRH 
exhibited Although CD44 receptors have been suggested as another potential target, 
investigation using nanoparticles formulated with hyaluronan in an in vivo biodistribution 
study found that intrapulmonary nebulized administration did not result in increased 
accumulation of the nanoparticles in the tumors [70]. 
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In addition to targeting tumor cells and pathogens, there are a number of immune cells which 
can be targeted for certain lung pathologies. In the case of tuberculosis, alveolar macrophages 
are recognized as a major part of the pathogenesis and thus a viable target for the delivery of 
antimicrobial agents. The Mycobacterium tuberculosis resides in the alveolar macrophages and 
forms the basis for the initiation of inflammation and the formation of granuloma. 
Macrophages are found in great numbers in the lungs and naturally possess the tendency to 
phagocytose particles under 5 µm, which can be capitalized for targeting. Formulating 
antibiotics in nanoparticles has been shown to increase the duration of therapeutic antibiotic 
concentration in the lungs and studies involving rifampicin, isoniazid and pyrazinamide 
indicated greater efficacy. Furthermore to phagocytic tendency, alveolar macrophages have 
also been identified with specific targets, including tetrapeptide tuftsin (Thr-Lys-Pro-Arg),O-
steroyl amylopectin (O-SAP) and macrophage scavenger receptors [71], as well as mannose 
receptors which are also in abundance on DCs. 
Activated T cells in the lung are another cell type which can be targeted in the case of asthma. 
These cells exhibit a Th2 phenotype, which is strongly associated with inducing airway 
inflammatory responses and chemo-attraction of inflammatory cells. Receptors for transferrin 
are known to be overexpressed in activated T cells, and in combination with polycations such 
as low molecular weight polyethylenimine, the conjugated form was investigated for use in 
asthma. Transferrin-polyethylenimine (Tf-PEI) could be used to selectively deliver small 
interfering RNA (siRNA) to activated T cells in the lung. SiRNA can be used to silence 
specific mRNA expression through incorporation into the host cell, and is a promising 
approach for not only asthma, but also other lung diseases such as cystic fibrosis, chronic 
obstructive pulmonary disease and cancer. Another cell group associated with asthma is the 
DCs, which are antigen presenting cells integral to the initiating immune responses. Although 
no specific study has been conducted targeting DCs by the pulmonary route, DCs exhibit 
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tendencies for nanoparticle uptake and several ligands such as DEC-205 have been identified 
[72]. These targeting possibilities could be useful in applications such as vaccines. 
In order to target the general lung epithelium for conditions such as asthma, lung structure cells 
have been investigated as potential targets, as β2-adrenergic receptors can be commonly found 
on bronchial smooth muscle cells. siRNA conjugated to salbutamol, which is a commonly used 
β2-AR agonist for asthma, has shown to exhibit greater gene silencing compared to the non-
conjugated siRNA. Another way of targeting the epithelial cells of the lungs is through the 
human polymeric immunoglobulin receptor (hpIgR) [73]. This approach is postulated to be 
useful in cystic fibrosis; delivering anti-proteases to the epithelial surface to counter the 
elastase released from neutrophils, which can otherwise result in unnecessary inflammation 
and subdued clearance.  
An interesting approach for increasing delivery of drugs into the epithelial tissue was tested by 
the administration of VEGF in an aerosolized form to increase permeability of microvessels in 
the lungs [74]. It has been hypothesized that the subsequent parenteral administration of 
magnetized nanoparticles containing the active molecule could potentially accumulate at the 
bronchial luminal epithelium through increased vascular endothelial permeability. Another 
example of magnetic targeting is the use of magnetic gradient fields to direct aerosol droplets 
containing superparamagnetic iron oxide nanoparticles to the desired regions of the lungs in 
mice. In addition to the delivery of particles to specific areas of the lung, the particles 
themselves can be used to release the active at specific areas based on physical external stimuli 
such as light, ultrasound, heat and electric or magnetic fields. An example of targeted release 
by external stimulus, is the use of ultrasound-sensitive microbubbles for local release of drugs 
[75] . Microbubbles created from lung surfactants showed a three-fold increase in targeted 
deposition of the drug compared to common lipid-only microbubbles.  
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In addition to the delivery of macromolecules to specific tissue and cells, intracellular 
organelles such as the mitochondria have also been investigated as pharmacological targets. 
The mitochondria has been proposed as a target for cancer, as it is integral for cell functioning, 
and involved in cell proliferation and apoptosis [76]. In order to target the mitochondria, a 
study investigated the use of histidine to assist with escape from endolysosomes after through 
the ‘proton sponge’ effect, which is essentially disruption of the endosomal membrane through 
osmotic swelling caused by the influx of protons [76]. Another approach for endosome escape 
was demonstrated by attachment of the active macromolecule to low molecular weight 
polyethylenimine, which has cellular uptake and endosomal escape properties, leading to 
relatively high gene transfer efficacy [77].  
There are indeed a vast number of identified targets for various cells involved in lung 
pathologies, but only a limited number have been investigated for efficacy after pulmonary 
delivery (Table 3). Despite the limited studies specifically for pulmonary delivery, numerous 
targets on cells of lung tissue and the local immune system have been identified for active 
targeting, and it may only be a matter of time before these molecular and physiological targets 
are investigated further for the delivery of therapeutic macromolecules. 
4. Conclusion: 
This review discusses the approaches for macromolecule delivery in the lungs, and strategies 
for targeted delivery based on different lung pathologies. The initial deposition of the 
formulation is mainly dictated by the aerosolization and inhalation, whereas the formulation in 
the various carriers can further influence the delivery of the macromolecule to specific cells 
such as immune cells and cancer cells. The targeted delivery of these macromolecules could 
potentially lead to therapy which has higher efficacy and lower side effects. 
5. Expert opinion: 
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Targeting the lung via non-invasive aerosolization of therapeutic macromolecules; requires a 
profound understanding of the macromolecule’s physicochemical characteristics, the 
formulation and carrier methods, the aimed inhaler device, and the pathophysiologic lung 
conditions.  
Macromolecules are a heterogeneous group of high molecular weight molecules (proteins, 
peptide-based molecules, and genetic material) with superior drug-like properties. The 
production of macromolecules is still a low yield high cost industry using mammalian cells. 
This also transfers to their use in developing formulations suitable for pulmonary delivery. 
Hence, the main challenges in their inhalation formulation development are heterogeneity, loss 
of their stability, poor loading capacity, susceptible for enzymatic, mucociliary and phagocytic 
clearances, immunogenicity, and toxicity. Carrier based delivery systems aim to overcome 
these challenges. 
Various carriers systems offer different physicochemical characteristics that might suit one 
type of macromolecule but not all. The carrier selection process is an active pool of research 
cross-matching optimization trying to optimize different macromolecules with different 
carriers under different formulation processes. Inclusive and vigorous characterization for each 
carrier and macromolecule-carrier combination is important to infer their clinical effectiveness 
and biocompatibility. It is a very tedious process involving in-vitro, and in-vivo animal, then 
human, experiments. Few of them will be clinically translated. The scalability and 
reproducibility of the formulation is another challenge which needs consideration prior 
designing carriers and is a major flaw of current methods involving solvent evaporation and 
ionic gelation. Methods such as microfluidics, which can overcome these issues regarding 
scaling up, are more frequently being investigated to improve the translation of preclinical 
formulations to the market [78]. Targeting moieties are important strategies to functionalize 
the formulation with homing facility that will prevent the non-specific delivery and increase 
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the therapeutic outcomes. The availability of biodegradable and biocompatible materials are 
fueling the development of new carriers which can be used for pulmonary delivery. NPs, MPs, 
dendrimers, Lipid-based, liposomes, and many other carriers have shown successful 
intracellular cargo delivery of proteins, peptides and DNA/RNAi. Currently, carriers based on 
viral or bacterial plasmids are seriously limited by their unfavorable immunogenicity, high 
costs, and low scalability.  
 
The delivery of the aerosolized formulation via the inhaler device still forms a significant 
aspect of pulmonary delivery, and the choice of device is based according to the patient 
condition, as well as the type of formulation. Although nebulizers, pMDI and DPI have many 
successful, well-established, market products, improvement are still required to use these 
devices for optimal delivery of macromolecules. It is important to consider approaches which 
can overcome issues such as low deposition, increasing the FPF, improving stability and shelf-
life, operate breath-independent and patient-friendly, and allow for multiuse without limiting 
their portability. 
Lastly, the pathophysiology of lung conditions is variable from one disease to another. Pre-
formulation evaluation for the characteristics of the target lung disease and subsequent 
manipulation of the macromolecule-carrier-device combination is required in order to achieve 
the desired delivery site, distribution, retention with reduced toxicity and immunogenicity, and 
better patient compliance. There is currently little known regarding the differences brought by 
lung diseases affecting the deposition and retention of active agents, which could be an avenue 
for future research. A need to produce pulmonary delivery systems that can address these 
limitations for each pulmonary pathology is a future tendency with achieving both site- and 
cell specific delivery.  
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Table 1. Aerosol generating devices advantages, disadvantages, and recent developments. 
 
Aerosol Device 
 
Advantages / Disadvantages 
 
Recent development for macromolecules delivery 
 
 
 
 
Nebulizers: 
Deliver the drug 
or drug solution 
mixture. 
 
Advantages 
• No breath-hold 
• Can be used by young, old or severely ill patients. 
• Minimal breath training 
• Drug concentration can be adjusted 
  
Disadvantages 
• Expensive and bulky 
• Nebulizers dose-delivery times are long  
• Contamination risk 
• Wet, cold mist 
• Newer liquid-based aerosol generators are being 
developed to improve upon the conventional nebulisation 
and increase the stability of active agents and the 
portability of the device. Forexamples: 
 
•  Respimat® Soft Mist™ Inhaler (Boehringer, Germany): 
the device generates aerosol upon actuation without a 
propellant but pressurized by mechanical means. 
 
• Surface Acoustic Wave (SAW) nebulizers: new devices 
that employ certain acoustic frequencies to generate 
liquid aerosols have proven efficient in macromolecule 
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• Power source needed, electricity or compressed gas 
• Less portable 
• Main limitation for macromolecule delivery is 
unstability of proteins while the nebulization 
process. 
 
nebulization [79].  
 
• Omron MicroAir® VMT (Omron Healthcare, IL, USA): 
using the vibrating mesh aerosol-generating technology 
 
  
• New systems are able to generate aerosols either under 
less harsh conditions; mechanically or through vibrating 
mesh.  
 
• They are useful for treatment of asthma, CF, and COPD, 
for example, rhDNase nebulized enzyme for therapeutic 
treatment of CF  
 
 
 
  
• Developments of MDI to improve the patient ease of use, 
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MDIs: 
Deliver the drug 
as liquid 
solution or 
suspension. 
Advantages 
 
• The most widely used oral inhalation device  
• Mobility/or portability 
• Short time required for delivery 
• Deposition of up to 20% of released dose into the 
airways 
Disadvantages 
• Hand-breath dependant 
• Inability to adjust the drug concentration 
• Failure of dose monitoring  
• Difficulty to use may aggravate the patient 
incompliance. 
•   Poor solubility of macromolecule liquid droplets 
increase the FPF and lowering the off target deposition, 
and minimize the drug preparation without limiting their 
portability, and increasing their cost. 
• The use of stabilizing or dispersing agents as sugars, 
surfactants, and ethanol during the formulation process 
improves the stability of macromolecules dispersed in the 
propellant and enhances the aerosol characteristics 
(FPF>50%) and lowers oropharyngeal deposition 
• Improvements in hand-breath coordination, portability 
• Accessory devices  that can improve the administration 
process: Bag: InspirEase, Holding chambers: 
Aerochamber, MediSpacer, ACE (Aerosol Cloud 
Chamber),  Spacer: OptiHaler 
• DNase has been successfully formulated and delivered 
through MDIs for CF [87].  
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in a propellant vehicle (currently 
Hydrofluroalkane). 
• Propellant allergy 
• Poor aerosol characteristics and off target 
deposition in the upper airways. 
• Expensive with new generations of MDIs 
 
 
 
 
 
 
 
 
 
Advantages 
• Small portable devices 
• No propellant 
• No hand to mouth coordination 
• Breath-actuated or energized aerosol generators do 
not require breath holding 
• Short dose-delivery  time 
• No cold effect 
 
• DPIs represent the popular choice for delivery of 
macromolecules through single dose devices [80]. 
Examples include HandiHaler™ (Boehringer Ingelheim, 
Germany), and Aerolizer™ (Novartis Pharma, CH). 
Multidose DPIs, i.e., Diskus™ (GlaxoSmithKline, UK) 
and Turbuhaler™ (AstraZeneca, Sweden), which are still 
being improved to enhance FPF of the generated aerosol. 
 
• Inefficient breath-actuated DPIs have been improved into 
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DPIs: 
Deliver spray-dried 
or lyophilized drug 
as fine dry powders 
clouds. 
• Countable doses and easily monitored 
• ~12-40% of the emitted dose is deposited into the 
airways. 
• Consistent stability with longer shelf life 
Disadvantages 
• Only available for limited number of drugs, due to 
production costs associated with challenging 
formulation of the active agent as a dry powder that 
exhibits flow-ability, disperse-ability, and stability 
• Breath-dependant might not have a sufficient 
inspiratory volume to stimulate the powder 
dispersion 
• De-agglomerating challenges to produce inhalable 
aerosols 
• Potential for off target deposition in the upper 
energized patient-independent devices, such as the 
Spiros™ (Dura Pharmaceuticals, CA, USA), that don’t 
eliminate the flow-rate need that might affect the drug 
deposition. 
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airways. 
• Unit dose might require reloading prior each use 
• Humidity might increase the size of hygroscopic 
particles favoring the deposition in upper airways 
and might affect the stability of macromolecules. 
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Table 2. Examples of aerosolized carriers for macromolecule delivery for lung pathologies.  
Indication 
or Disease 
Therapeutic 
Macromolecule 
Carrier/devi
ce 
Type of study Outcome/efficacy Refer
ences 
 
 
 
 
 
 
 
 
 
• W-1 L19 
 
PLGA NP Preclinical in 
vitro cell assay 
PLGA NPs were successfully 
formulated and loaded with W-1 L19 
oligopeptides prepared from a highly 
immunogenic part VP2 capsid 
protein of Canine parvovirus (CPV). 
These NPs were successfully 
uptaken on J-774 cell lines with a 
non-toxic nitric oxide production and 
high immune response that could be 
a promising vaccine against CPV 
[81]
. 
• Ricin Vaccine Liposome Preclinical in 
vivo mouse 
A liposomal preparation of a natural 
toxoid A-chain of Ricin which is 
[82] 
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Aerosolised 
Vaccines 
assay natural Lectin from Ricinus 
communis plant that was sucessfuly 
delivered by aerosols into mice lung.  
• Pneumococcal 
surface protein A 
(PspA) 
 
NPMP via 
DPI 
Preclinical in 
vivo mouse 
assay 
NPMPs particles as DPI and in-vivo 
lung instillation in mice induced 
successful lung immunity.  
[39] 
• Tuberculosis (TB) 
: Anti-TB vaccine 
Muramyl 
dipeptide 
Instillation Preclinical in-
vivo mouse 
assay 
Mycobacterium bovis Bacille 
Calmette-Guérin (BCG) was 
successfully intratracheal instillation 
in mice model of TB and compared 
to the subcutaneous route to find 
stronger mucosal lung immunity 
induced.   
[83] 
Acute Surfactant Proteins  DPI, in-vivo animal Different surfactant proteins were [84-
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Respiratory 
Distress 
Syndrome 
(ARDS) 
nebulization, 
instillation 
study delivered to the lung via aerosols as 
dry powders, nebulized or instillations 
in various in-vivo animal models of 
acute lung injury. 
86] 
 
Cystic 
Fibrosis (CF) 
 
 
 
Primary 
Ciliary 
Dyskinesia 
(PCD) 
A purified solution of 
recombinant human 
deoxyribonuclease 
(rhDNase),  
 
 
a mucolytic agent 
reducing mucous 
viscosity and 
secretions. 
 
Nebulized or 
MDI 
 
In clinics 
Nebulised protein or MDIs  
[Approved by FDA, Genenzyme 
NCT01712334] 
[87] 
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Lung 
transplant 
 
Cyclosporin A  
 
 
Nebulized 
 
Phase III clinical 
trails 
 
Cyclosporin A was delivered via 
nebulized aerosols that showed high 
absorption and lung retention lung 
recipient in a randomized, double-blind, 
placebo-controlled clinical trial that 
showed improved the outcomes in 
chronic rejections. 
 
[88] 
Lung Cancer 
and 
Metastasis 
• Interleukin-2 
 
Nebulized Clinical trials 
phase III 
Multicentre clinical trial showed high 
efficient delivery with low toxicity 
through nebulised aerosols. 
[89] 
• IgG1 Nebulized In-vitro study Nebulised monoclonal antibodies 
against A431 cells showing promising 
[90]. 
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results  for lung cancer. 
• Gene delivery: 
Akt1 siRNA 
NP In-vivo animal 
study 
Aerosol Delivery of nanoparticle PEI 
of Akt1 siRNA Significantly 
Suppresses Lung Tumorigenesis in K-
rasLA1 Mice. 
[21] 
 
Alpha-1-
antitrypsin 
deficiency 
Emphysema 
CF 
 
Alpha1 proteinase 
inhibitor 
(Alpha-1-
Antitrypsin) 
 
 
 
Nebulized 
 
Clinical trials 
phase II/III 
 
Nebulized Alpha-1-Antitrypsin was 
well tolerated in patient with CF in 
phase II/III clinical trials in Europe. 
(ClinicalTrials.gov: NCT01684410) 
[91] 
 
Table 3. Summary of targets investigated specifically for formulations administered by the pulmonary route for lung pathologies. 
Ac
ce
pte
d M
an
us
cri
pt
50 
 
Disease Target Effect Reference 
Lung cancer Carbonic anhydrase IX 
(CPP33 dual-ligand 
modified triptolide-loaded 
liposomes) 
Rats that were endotracheally administered triptolide-loaded liposomal 
formulations exhibited enhanced triptolide-loaded anti-cancer efficacy 
and reduced concentration of TPL in systemic circulation without 
apparent systemic toxicity. 
[92] 
Lung cancer SP5-52 peptide (conjugated 
to Gem-loaded SFNPs) 
Targeted formulations exhibited higher survival rate, less mortality, and 
no sign of metastasis in a lung tumor model. 
[93] 
Lung cancer Hyaluronic acid (HA) In vivo biodistribution studies with intrapulmonary nebulized 
administration of nanoparticle formulated with hyaluronic acid, did not 
result in increased accumulation in the tumors. 
[94] 
Lung cancer High MMP9 concentration 
 
Mesoporous silica-based nanoparticles functionalized with bioresponsive 
caps exhibited proteasome inhibitor release at high MMP 9 
[95] 
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concentrations in a lung cancer cell line transfected with MMP9 cDNA. 
Lung cancer luteinizing hormone 
releasing hormone (LHRH) 
receptors 
tumor-targeted local delivery by inhalation of anticancer drugs and 
mixture of siRNAs was exhibited in a mouse orthotopic model of human 
lung cancer 
[96] 
Lung cancer Integrin avb3 In vitro tumor cell uptake study using RGDfk-histidine-PLGA NPs, 
suggested that receptor mediated uptake could be taking place. 
[97] 
Cystic firbrosis Human polymeric 
immunoglobulin receptor 
(hpIgR) 
Antiprotease delivery through conjugation to an antibody correlated with 
areas of hpIgR expression in the respiratory epithelium in an in vivo 
study. 
[73] 
Asthma Beta2-adrenergic receptor 
(β2-AR 
SiRNA conjugated to salbutamol exhibited greater gene silencing 
compared to the non-conjugated siRNA in an in vivo study. 
[98] 
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Asthma Transferrin receptor (TfR) Biodistribution study of siRNA, transferrin-polyethylenimine polyplexes 
in an in vivo model confirmed efficient and selective delivery of siRNA 
to activated T cells. 
[77] 
 
 
